learn HMI-115
much-hyped research compound targeting prolactin receptor in scalp
- HMI-115: Frequently Asked Questions About Hair Loss Treatment HMI-115 is an investigational anti-prolactin-receptor antibody being trialled for androgenetic alopecia. It is not approved anywhere; its hair-loss evidence is a 16-person Phase 1b announced only by press release, plus a completed 192-man Phase 2 in China whose results are not yet published.
- What is HMI-115 and how is it different from common treatments like minoxidil? HMI-115 (BAY 1158061) is an investigational monoclonal antibody that blocks the prolactin receptor, not a GnRH antagonist. It is given by injection in trials and is not approved anywhere; minoxidil is an approved topical vasodilator with decades of published data, while HMI-115's hair-loss trial results remain unpublished.
- Is HMI-115 taken orally, applied on the scalp, or injected? HMI-115 is administered as an injection.
- All 5 questions on HMI-115 →

